Zobrazeno 1 - 10
of 154
pro vyhledávání: ''
Autor:
Takaaki Tokito, Akihiro Bessho, Satoshi Igawa, Shinji Sasada, Nobuhiko Seki, Naoki Furuya, Yosuke Tanaka, Koichi Minato, Kaoru Kubota, Hideki Hayashi, Hirotoshi Iihara, Rintaro Noro, Takayuki Kaburagi, Tsuneo Shimokawa, Hiroaki Okamoto, Masanao Nakashima, Shingo Miyamoto, T. Hirose, Toshiyuki Harada
Publikováno v:
Lung Cancer. 161:49-54
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity associated with this agent often leads to dose modifications. The aim
Autor:
Bingjie Fan, Shijiang Wang, Jinming Yu, B. Li, Wanlong Li, Dai Zhang, Linlin Wang, Bing Zou, Xuanzong Li
Publikováno v:
Lung Cancer. 151:39-43
B-cell lymphoma 2-like 11 (BCL-2-like 11, BCL2L11, also known as BIM) deletion polymorphism (BIM-del) has been associated with resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and is a poor progn
Autor:
Anas Gazzah, Pilar Garrido, Alexis B. Cortot, Jaafar Bennouna, Melissa Lynne Johnson, Maciej Gil, Haruyasu Murakami, Benjamin Besse
Publikováno v:
Lung Cancer. 142:63-69
Objectives Efficacy and safety of necitumumab when combined with pembrolizumab was assessed in patients with Stage IV non-small cell lung cancer (NSCLC) of squamous and nonsquamous histology, who had progressed after treatment with a platinum-based d
Autor:
Amy T.Y. Chang, Tony Mok, Frankie Mo, Jacky Y.C. Li, Oscar S.H. Chan, Ki Wang, Catherine Y.H. Wong, Rebecca M.W. Yeung, Kwok Chi Lam, Frankie P. T. Choi
Publikováno v:
Lung Cancer. 142:41-46
Objectives NSCLC patients harboring EGFR mutation invariably developed resistance to EGFR TKI. We postulated that oligoresidual disease (ORD) after initial TKI might harbor resistant clones. This study aimed to test if preemptive local ablative thera
Autor:
Alvin Soon Tiong Lim, Quan Sing Ng, Anantham Devanand, Daniel S.W. Tan, T. Rajasekaran, Eng Huat Tan, Zaw Win Aung, Chee Keong Toh, G. Lai, Chow Wei Too, Tony Kiat-Hon Lim, Aaron C. Tan, Bien Soo Tan, Tina P.T. Koh, Tse Hui Lim, Mei-Kim Ang, Angela Takano, Wan Ling Tan, Shou Yu Poon, Brett Doble, Apoorva Gogna, Amit Jain, Boon-Hean Ong, Ravindran Kanesvaran, Wan-Teck Lim, Gek San Tan
Publikováno v:
Lung Cancer. 139:207-215
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsie
Autor:
Masayuki Takeda, Kaoru Tanaka, Kimio Yonesaka, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Takayuki Takahama, Ryoji Kato, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Lung Cancer. 139:28-34
Objectives The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between
Autor:
Encarnação Teixeira, Sousa Ac, Martins J, Janeiro A, Malveiro S, M. Felizardo, Oliveira Ar, Nogueira F, Maria Carmo-Fonseca, Silveira C
Publikováno v:
Lung Cancer. 139:35-40
Objectives Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR-targeted therapies collectively known as tyrosine kinase inhibitors (TKI
Publikováno v:
Lung Cancer. 138:52-57
Brain metastasis (BM) is common in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. However, the brain surveillance strategy during treatment in advanced lung cancer patients varies, and the impact on clinical outcome is uncl
Autor:
Camille Mehlman, Etienne Giroux Leprieur, Valérie Gounant, Pierre Olivier Schischmanoff, Gaelle Rousseau-Bussac, Thierry Chinet, B. Duchemann, Jean Trédaniel, Cécile Dujon, Nicolas Girard, Jacques Cadranel, Céline Callens, Roger Lacave, Anaïs Pujals, Nathalie Théou-Anton, Hélène Blons, Sylvie Friard
Publikováno v:
Lung Cancer
Lung Cancer, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
Lung Cancer, Elsevier, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
Lung Cancer, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
Lung Cancer, Elsevier, 2019, 137, pp.149-156. ⟨10.1016/j.lungcan.2019.09.019⟩
International audience; Objectives: The understanding of histo-molecular mechanisms associated with resistance to osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-mutated Non-Small-Cell-Lung-Cancer (NSCLC).Mate
Autor:
Seonghae Yoon, Hoon Gu Kim, Jae Yong Cho, Ji Youn Han, Eun Kyung Cho, Byoung Chul Cho, Jin-Soo Kim, Kyung Hee Lee, Ho Jung An, Jong Seok Lee, Jin Hyoung Kang, Keunchil Park, Dae Ho Lee, Ka Young Hong, Dong Wan Kim, Ki Hyeong Lee, Bong Seog Kim, In Jin Jang, Oak Pil Han, Young Joo Min, Young Su Noh
Publikováno v:
Lung Cancer. 135:66-72
Objectives The aim of this phase 1/2 study was to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of olmutinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who had fail